Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials

Claudins are major components of tight junctions that maintain cell polarity and intercellular adhesion. The dynamics of claudins in Cancer cells have attracted attention as a therapeutic target. During carcinogenesis, claudin expression is generally downregulated; however, overexpression of claudin-18.2 has been observed in several types of cancers. Upregulated and mislocalized claudin-18.2 expression in Cancer cells has been suggested as a therapeutic target. Research on claudin-18.2 has revealed its involvement in carcinogenesis. Clinical trials using zolbetuximab, a monoclonal antibody targeting claudin-18.2, for patients with advanced Cancer yielded positive results with few high-grade adverse events; thus, it is expected to be a novel and effective therapeutic. Here, we review current insights into the role that claudin-18.2 plays in basic Cancer research and clinical applications. A better understanding of these roles will facilitate the development of new treatment strategies for Cancer patients with poor prognoses.